Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1967 1
1971 2
1972 2
1973 1
1974 1
1978 4
1979 1
1980 2
1981 7
1982 2
1983 3
1984 5
1985 4
1986 3
1987 3
1988 1
1989 5
1990 8
1991 1
1992 1
1993 5
1994 9
1995 4
1996 7
1997 4
1998 7
1999 6
2000 13
2001 12
2002 10
2003 5
2004 10
2005 12
2006 21
2007 11
2008 14
2009 20
2010 13
2011 26
2012 20
2013 24
2014 35
2015 20
2016 18
2017 32
2018 21
2019 38
2020 33
2021 51
2022 42
Text availability
Article attribute
Article type
Publication date

Search Results

547 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS. Antonarakis ES, et al. Among authors: tabata ki. J Clin Oncol. 2020 Feb 10;38(5):395-405. doi: 10.1200/JCO.19.01638. Epub 2019 Nov 27. J Clin Oncol. 2020. PMID: 31774688 Free PMC article. Clinical Trial.
Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice.
Tanaka S, Hikita H, Tatsumi T, Sakamori R, Nozaki Y, Sakane S, Shiode Y, Nakabori T, Saito Y, Hiramatsu N, Tabata K, Kawabata T, Hamasaki M, Eguchi H, Nagano H, Yoshimori T, Takehara T. Tanaka S, et al. Among authors: tabata k. Hepatology. 2016 Dec;64(6):1994-2014. doi: 10.1002/hep.28820. Epub 2016 Oct 21. Hepatology. 2016. PMID: 27637015
Age-dependent loss of adipose Rubicon promotes metabolic disorders via excess autophagy.
Yamamuro T, Kawabata T, Fukuhara A, Saita S, Nakamura S, Takeshita H, Fujiwara M, Enokidani Y, Yoshida G, Tabata K, Hamasaki M, Kuma A, Yamamoto K, Shimomura I, Yoshimori T. Yamamuro T, et al. Among authors: tabata k. Nat Commun. 2020 Aug 18;11(1):4150. doi: 10.1038/s41467-020-17985-w. Nat Commun. 2020. PMID: 32811819 Free PMC article.
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.
Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Dejima H, et al. Among authors: tabata k. Nat Commun. 2021 May 11;12(1):2722. doi: 10.1038/s41467-021-22890-x. Nat Commun. 2021. PMID: 33976164 Free PMC article.
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y. Kato Y, et al. Among authors: tabata k. PLoS One. 2019 Feb 27;14(2):e0212513. doi: 10.1371/journal.pone.0212513. eCollection 2019. PLoS One. 2019. PMID: 30811474 Free PMC article.
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.
Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Hu X, et al. Among authors: tabata k. Nat Commun. 2019 Jul 5;10(1):2978. doi: 10.1038/s41467-019-10877-8. Nat Commun. 2019. PMID: 31278276 Free PMC article.
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M; Japanese Urological Oncology Group (JUOG). Shiota M, et al. Among authors: tabata ki. Cancer Sci. 2021 Apr;112(4):1524-1533. doi: 10.1111/cas.14722. Epub 2021 Feb 13. Cancer Sci. 2021. PMID: 33159829 Free PMC article.
547 results